ClinicalTrials.gg
RecruitingNCT06888908Updated Mar 21, 2025

Changes in Perioperative Blood Volume and Fluid Distribution in Patients Undergoing Primary Total Hip Replacement.

An observational study in Hip Arthroplasty Replacement, sponsored by Copenhagen University Hospital, Hvidovre. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Copenhagen University Hospital, Hvidovre · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 38 studies in Hemorrhage with a site in Denmark — 6 open to participants now, 9 under way, 2 of them phase 3. Hemorrhage · Denmark.

Planned enrollment
10th of 12
25 · median 88
Started
2025
with 1 other
Observational
14 of 38
3 open now
Registered
36th of 38
by date
Lead sponsor
1 of 38
Copenhagen University Hospital, Hvidovre

Among the 38 studies in Hemorrhage with a site in Denmark, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, and was the 36th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

6 of the 38 studies in Hemorrhage with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Hemorrhage with a site in Denmark, or all of them as a file.
02

Study summary

Clinical assessment of bleeding and calculation of perioperative blood loss do not provide an accurate estimate of blood volume. This makes rational fluid management difficult, which is of high importance for patient-related outcomes. The availability of carbon monoxide(CO)-rebreathing allows for simple, non-invasive and precise measurement of changes in blood volume.

The purpose of the study is to investigate and describe changes in blood volume and fluid distribution perioperative in patients undergoing total hip arthroplasty. Furthermore, to investigate the association between changes in blood volume and incidence of orthostatic insufficiency.

03

Conditions studied

  • Hip Arthroplasty Replacement

Browse trials for

Keywords

  • Blood loss
  • Blood volume
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for an elective total hip arthoplasty (THA) at Hvidovre University Hospital and undergo the proceduce under spinal anesthesia with propofol sedation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for an elective total hip arthoplasty (THA) in a standardized fast track setting.
  • Capable of participating in CO-rebreathing measurement
  • Age ≥ 18 years
  • Able to speak and understand Danish
  • Has provided written .

Exclusion criteria

Exclusion Criteria:

  • Intraoperative blood loss exceeding 750 mL.
  • Perioperative need for a blood transfusion.
  • Confirmed or suspected coagulopathies.
  • Factors that make CO-rebreathing measurement impossible.
  • Known orthostatic intolerance.
  • physical status (ASA) classification ≥ 4.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in total blood volume (TBV)

    Measured in milliliter (mL)

    Time frame: Preoperatively and 6 hours postoperatively

Secondary outcomes

  1. Change in total blood volume (TBV)

    measured in mL

    Time frame: Preoperatively and 24 hours postoperatively

  2. Changes in total hemoglobin mass (tHgb)

    Measured in gram (g)

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  3. Changes in erythrocyte volume (EBV)

    Measured in mL

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  4. Changes in plasma volume (PV)

    Measured in mL

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  5. Changes in hematokrit (Ht)

    Reported as percentage(%)

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  6. Changes in hemoglobin (Hg) concentration

    Measured in millimoles/liter(mmol/L)

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  7. Changes in Total body water(TBW), intra-(ICF) and extracellular(ECF) fluid distribution

    Full body water via bioelectrical impedance analysis. The individual components are reported in L and percent.

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  8. Changes in C-Reactive Protein (CRP)

    Measured in milligram/liter (mg/L)

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  9. Incidence of orthostatic intolerance during mobilization

    Symptoms of orthostatic intolerance: dizziness, nausea, vomiting, blurry vision or syncope during mobilization

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  10. Association between total blood loss and incidence of orthostatic intolerance

    Blood loss measured in mL. Symptoms of orthostatic intolerance: dizziness, nausea, vomiting, blurry vision or syncope during mobilization

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  11. Association between changes in C-Reactive Protein and total blood loss

    C-Reactive Protein measured in mg/L and total blood loss measured in mL

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  12. Association between peripheral perfusion index and total blood loss

    Peripheral perfusion index measured in percent and total blood loss in mL

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

  13. Association between total hemoglobin (SpHb) and total blood loss

    SpHb measured as gram/deciliter and total blood loss measured in mL

    Time frame: Preoperatively, 6 hours postoperatively and 24 hours postoperatively

Other outcomes

  1. Intraoperativ estimation of bleeding

    Measured by weighting gauze (gram)

    Time frame: Intraoperative at end of the surgical procedure

  2. Intraoperative bleeding

    Measured by visual estimation in surgical drains (mL)

    Time frame: Intraoperative at end of the surgical procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Sep 2026, 18 months later.

Of 134 non-industry observational studies under Hemorrhage, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 78. This study's planned 18 months is below that.

Counting every sponsor, half of 158 studies reached it within 33 months; a quarter within 15 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2025
First posted
Mar 21, 2025
StartEst.
Mar 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888908
Lead sponsor
Copenhagen University Hospital, Hvidovre
Responsible party
Puk Kristiansen (MD, Ph.d.-student, Copenhagen University Hospital, Hvidovre) — Principal investigator
First posted
Mar 21, 2025
Start date
Mar 2025 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Mar 21, 2025

Study contacts

Puk Kristiansen, MD
Contact
puk.kristiansen@regionh.dk
+4530291189
Ana-Marija Hristovska, Senior registrar, Ph.D.
Contact
ana-marija.hristovska.02@regionh.dk
Nicolai Foss, Professor, Dr. Med.
study director · Department of Anesthesiology and Intensive Care Medicine, Copenhagen University Hospital, Hvidovre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion